ArticleEndocrine connections2026
Short-term changes in des-acyl ghrelin following bariatric surgery.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bariatric surgery affects multiple physiological systems, including the regulation of des-acyl ghrelin (DAG). DAG has been negatively associated with excess adiposity and insulin resistance. Objectives: To assess the relationship between serum DAG concentrations and short-term weight loss following bariatric surgery. Setting: Prospective multicenter cohort study across three bariatric surgery centers in Latvia. Methods: Fasting blood samples for DAG measurement were collected 1 day preoperatively, 2 days postoperatively, and at 3 months post-surgery. Anthropometric and laboratory assessments were performed at the same time points. Results: A total of 62 patients were included; 64.5% (n = 40) underwent Roux-en-Y gastric bypass (RYGB), and 35.5% (n = 22) sleeve gastrectomy (SG). The cohort was predominantly female (67.7%). Median baseline weight and BMI were 129 kg (IQR 106-150) and 45.1 kg/m2, respectively. Median excess weight loss at 3 months was 40.2% (IQR 32.2-54.3%). DAG concentrations showed significant inverse correlations with preoperative weight (r = -0.371), BMI (r = -0.311), and excess weight (r = -0.355; all P < 0.05). These associations persisted across all sampling points in the RYGB group, whereas in SG patients, they were largely confined to postoperative day 2. No significant relationships were observed between DAG and relative weight-loss metrics. DAG levels were higher in females; age showed no association with DAG changes. Conclusion: DAG levels are inversely associated with absolute measures of adiposity, particularly among RYGB patients. These findings support DAG's potential relevance as a marker of total fat burden and early postoperative metabolic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.